Randomized placebo controlled trial of nabilone for agitation in Alzheimer's disease

Agitation, seen in 20-50% of those with moderate-to-severe Alzheimer's disease (AD),1,2 is particularly common in long-term care facility residents3,4 and a challenging neuropsychiatric symptom (NPS) to treat. Agitation is associated with decreased quality of life, increased caregiver burden, and higher rates of institutionalization and mortality.3,5 Nonpharmacological interventions are considered first-line therapy for the management of agitation in AD. However, with severe agitation, when nonresponsive to nonpharmacological interventions, judicious use of pharmacological interventions is recommended.
Source: The American Journal of Geriatric Psychiatry - Category: Geriatrics Authors: Tags: Regular Research Article Source Type: research